Influenza

New COVID-19 Hygiene Measure To Be Available This Fall

Wednesday, July 8, 2020 - 12:30pm

FEND cleans the air passages of the droplets of airway lining fluid we generate on natural breathing.

Key Points: 
  • FEND cleans the air passages of the droplets of airway lining fluid we generate on natural breathing.
  • Cleaning the airways of these particles reduces the risk of infection movement into and out of the lungs, a hygiene benefit to the user and to the environment.
  • "Around 80% of these particles are less than a single micron in size, and not effectively filtered by conventional face masks.
  • The Company will launch FEND in the fall 2020 for use as an essential hygienic protection against COVID-19 and other airborne infectious diseases, like influenza.

New COVID-19 Hygiene Measure To Be Available This Fall

Wednesday, July 8, 2020 - 12:30pm

FEND cleans the air passages of the droplets of airway lining fluid we generate on natural breathing.

Key Points: 
  • FEND cleans the air passages of the droplets of airway lining fluid we generate on natural breathing.
  • Cleaning the airways of these particles reduces the risk of infection movement into and out of the lungs, a hygiene benefit to the user and to the environment.
  • "Around 80% of these particles are less than a single micron in size, and not effectively filtered by conventional face masks.
  • The Company will launch FEND in the fall 2020 for use as an essential hygienic protection against COVID-19 and other airborne infectious diseases, like influenza.

New Paper Documents Effectiveness Of Natural Physiological Salts As New Hygienic Intervention To Reduce The Exhalation Of Particles That Transmit Airborne Infectious Disease

Tuesday, July 7, 2020 - 3:54pm

"Airborne infectious disease transmits through the air by particles we exhale during natural breathing," said the lead author, Dr. David Edwards of Harvard University and Founder of Sensory Cloud.

Key Points: 
  • "Airborne infectious disease transmits through the air by particles we exhale during natural breathing," said the lead author, Dr. David Edwards of Harvard University and Founder of Sensory Cloud.
  • "Most of these particles are less than a single micron in size, and not effectively filtered by conventional face masks.
  • Most of the suppressed airborne particles were smaller in size than those effectively filtered by conventional face masks.
  • The Company will launch FEND in the fall 2020 for use as a new hygienic protection against COVID-19 and other airborne infectious diseases, like influenza.

New Paper Documents Effectiveness Of Natural Physiological Salts As New Hygienic Intervention To Reduce The Exhalation Of Particles That Transmit Airborne Infectious Disease

Tuesday, July 7, 2020 - 3:46pm

"Airborne infectious disease transmits through the air by particles we exhale during natural breathing," said the lead author, Dr. David Edwards of Harvard University and Founder of Sensory Cloud.

Key Points: 
  • "Airborne infectious disease transmits through the air by particles we exhale during natural breathing," said the lead author, Dr. David Edwards of Harvard University and Founder of Sensory Cloud.
  • "Most of these particles are less than a single micron in size, and not effectively filtered by conventional face masks.
  • Most of the suppressed airborne particles were smaller in size than those effectively filtered by conventional face masks.
  • The Company will launch FEND in the fall 2020 for use as a new hygienic protection against COVID-19 and other airborne infectious diseases, like influenza.

Carpenter Technology Provides Updated Outlook and Continues Actions to Bolster Already Healthy Liquidity Position

Monday, July 6, 2020 - 1:00pm

However, this was a prudent decision to strengthen our already healthy balance sheet and liquidity position in this challenging environment.

Key Points: 
  • However, this was a prudent decision to strengthen our already healthy balance sheet and liquidity position in this challenging environment.
  • The COVID-19 pandemic has presented a near-term challenge for Carpenter Technology, as it has for all in the industry.
  • Carpenter Technology has expanded its AM capabilities to provide a complete end-to-end solution to accelerate materials innovation and streamline parts production.
  • Any of these factors could have an adverse and/or fluctuating effect on Carpenter Technologys results of operations.

A New Swine Flu Threat Brings 1918 and 2009 Pandemic Deja Vu

Friday, July 3, 2020 - 2:15pm

BALTIMORE, July 3, 2020 /PRNewswire/ --It was just reported that the H1N1 Swine Flu which caused pandemics in 1918 and 2009 may soon return.

Key Points: 
  • BALTIMORE, July 3, 2020 /PRNewswire/ --It was just reported that the H1N1 Swine Flu which caused pandemics in 1918 and 2009 may soon return.
  • Ironically, it is the threat of a new strain of deadly H1N1 Swine Flu that may begin our return-to-normal in just a few months.
  • In 2009, H1N1 Swine Flu influenza researchers strongly recommended that all health-care workers and patients be tested & treated for Vitamin D Deficiency known as VDD [PMID: 20102323].
  • Key to preventing the Swine Flu is to treat the decade-old ignored global pandemic of VDD.

NuGenerex Immuno-Oncology Announces Plans to Address the New Emerging Pandemic Threat from G4 EA H1N1 Swine Influenza Virus Using Ii-Key-H1 Peptide Vaccine

Thursday, July 2, 2020 - 2:00pm

Prevalent Eurasian Avian-like H1N1 Swine Influenza Virus with 2009 Pandemic Viral Genes Facilitating Human Infection.

Key Points: 
  • Prevalent Eurasian Avian-like H1N1 Swine Influenza Virus with 2009 Pandemic Viral Genes Facilitating Human Infection.
  • (See Link) https://www.pnas.org/content/early/2020/06/23/1921186117?referringSource...
    MIRAMAR, Fla., July 02, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology today announced that the company is launching a vaccine development effort to address the new, emerging pandemic threat from a newly identified swine influenza virus.
  • This emerging virus is similar to the 2009 swine flu virus that is estimated to have killed nearly 500,000 globally.
  • Now, as another pandemic threat is emerging with G4 SA H1N1 swine influenza, we are in position to rapidly respond with our Ii-Key-H1 peptide vaccine for which we have Phase I clinical safety and immunogenicity data.

Quantabio RT-qPCR ToughMix Given Expanded Role in CDC COVID-19 Testing Protocol

Wednesday, July 1, 2020 - 1:05pm

The CDC first added Quantabios UltraPlex 1-Step ToughMix and qScript XLT 1-Step RT-qPCR ToughMix to its protocol for the 2019-Novel Coronavirus Real-Time RT-PCR Diagnostic Panel in April 2020.

Key Points: 
  • The CDC first added Quantabios UltraPlex 1-Step ToughMix and qScript XLT 1-Step RT-qPCR ToughMix to its protocol for the 2019-Novel Coronavirus Real-Time RT-PCR Diagnostic Panel in April 2020.
  • Due to the global shortage of nucleic acid extraction reagents, CDC recently amended the EUA protocol to include a heat treatment methodology, using UltraPlex 1-Step ToughMix, as a viable alternative to RNA extraction.
  • Over the past seven years, Quantabio has actively supported development of testing protocols for influenza, polio and other infectious diseases, said Heather Meehan, PhD, Vice President and Head of Quantabio.
  • The UltraPlex 1-Step ToughMix overcomes common PCR inhibitors, delivers superior performance and enables laboratories to continue testing for COVID-19 despite the global reagent supply issues.

Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial

Wednesday, July 1, 2020 - 11:00am

In addition, pandemic influenza, such as the H1N1 Swine Flu pandemic of 2009, is a constant global threat.

Key Points: 
  • In addition, pandemic influenza, such as the H1N1 Swine Flu pandemic of 2009, is a constant global threat.
  • BiondVax (NASDAQ: BVXV) is a Phase 3 clinical stage biopharmaceutical company developing a universal flu vaccine.
  • In a total of seven completed Phase 1/2 and Phase 2 clinical trials enrolling 818 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic.
  • The ongoing pivotal Phase 3 clinical trial aims to assess safety and effectiveness of M-001 in reducing flu illness and severity.

Dr. Reddy’s Partners with FUJIFILM and Global Response Aid for Avigan® (favipiravir), a Potential Treatment of COVID-19

Wednesday, July 1, 2020 - 9:10am

Further, FUJIFILM would receive an upfront license fee and royalties on sales from Dr. Reddys and GRA.

Key Points: 
  • Further, FUJIFILM would receive an upfront license fee and royalties on sales from Dr. Reddys and GRA.
  • FUJIFILM will provide Dr. Reddys and GRA with an array of data on Avigans preclinical and clinical studies that FUJIFILM has accumulated thus far.
  • Dr. Reddys and GRA will use this data for clinical studies targeting COVID-19 in regions where infection has been spreading.
  • Avigan Tablet, developed by FUJIFILM Toyama Chemical, was approved for manufacture and sale in Japan in 2014 as an influenza antiviral drug.